Literature DB >> 17129812

General principles and pharmacology of biologics in inflammatory bowel disease.

Patricia L Kozuch1, Stephen B Hanauer.   

Abstract

The pharmacology of each biologic agent is important regarding the dose required to achieve benefits, duration of therapeutic effect, and the induction of immunogenicity. Comprehension of the individual pharmacology, pharmacodynamics, and pharmacokinetics, in addition to the impact of concomitant immunomodulation on immunogenicity allows optimization of each biologic agent in the appropriate inductive or maintenance setting of IBD.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17129812     DOI： 10.1016/j.gtc.2006.09.005

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN： 0889-8553            Impact factor:   3.806


  9 in total

Review 1.  Nuclear receptors and inflammatory diseases.

Authors:  Kun Wang; Yu-Jui Yvonne Wan
Journal:  Exp Biol Med (Maywood)       Date:  2008-03-28

Review 2.  Ulcerative colitis: immune function, tissue fibrosis and current therapeutic considerations.

Authors:  Jochen Maul; Martin Zeitz
Journal:  Langenbecks Arch Surg       Date:  2011-04-09       Impact factor: 3.445

3.  Approach to Optimize Anti-TNF-α Therapy in Patients With IBD.

Authors:  Yuga Komaki; Fukiko Komaki; Atsushi Sakuraba; Russell Cohen
Journal:  Curr Treat Options Gastroenterol       Date:  2016-03

4.  Effects of the ACE2 inhibitor GL1001 on acute dextran sodium sulfate-induced colitis in mice.

Authors:  John J Byrnes; Stefan Gross; Courtney Ellard; Kelly Connolly; Stephen Donahue; Dominic Picarella
Journal:  Inflamm Res       Date:  2009-06-11       Impact factor: 4.575

Review 5.  Review and clinical perspectives for the use of infliximab in ulcerative colitis.

Authors:  R Panaccione; R N Fedorak; G Aumais; Edmond-Jean Bernard; C N Bernstein; A Bitton; K Croitoru; L A Dieleman; R Enns; B G Feagan; D Franchimont; G R Greenberg; Anne-Marie Griffiths; J K Marshall; P Pare; S Patel; R Penner; C Render; E Seidman; A Hillary Steinhart
Journal:  Can J Gastroenterol       Date:  2008-03       Impact factor: 3.522

Review 6.  Profile of certolizumab and its potential in the treatment of psoriatic arthritis.

Authors:  Maria Sole Chimenti; Rosita Saraceno; Andrea Chiricozzi; Alessandro Giunta; Sergio Chimenti; Roberto Perricone
Journal:  Drug Des Devel Ther       Date:  2013-04-15       Impact factor: 4.162

7.  Efficacy of Early Infliximab Treatment for Pediatric Crohn's Disease: A Three-year Follow-up.

Authors:  Yun Seok Lee; Sang Hun Baek; Mi Jin Kim; Yoo Min Lee; Yoon Lee; Yon Ho Choe
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2012-12-31

8.  Biologic targeting in the treatment of inflammatory bowel diseases.

Authors:  Matteo Bosani; Sandro Ardizzone; Gabriele Bianchi Porro
Journal:  Biologics       Date:  2009-07-13

Review 9.  Application of prodrugs to inflammatory diseases of the gut.

Authors:  Helieh S Oz; Jeffrey L Ebersole
Journal:  Molecules       Date:  2008-02-27       Impact factor: 4.411
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.